Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death

Abstract Background Sorafenib (Sor) is the only approved multikinase inhibitor indicated for the treatment of HCC. Previous studies have shown that amygdalin (Amy) possesses anticancer activities against several cancer cell lines; we suggested that these compounds might disrupt AMPK/mTOR and BCL-2....

Full description

Bibliographic Details
Published in:BMC Complementary Medicine and Therapies
Main Authors: Tarek El-Sewedy, Afrah Fatthi Salama, Amro E. Mohamed, Nashwa M. Elbaioumy, Ali H. El-Far, Aisha Nawaf Albalawi, Alaa Elmetwalli
Format: Article
Language:English
Published: BMC 2023-09-01
Subjects:
HCC
AMPK /mTOR
Angiogenesis
Sorafenib
Molecular docking
Amygdalin
Online Access:https://doi.org/10.1186/s12906-023-04142-1

Internet

https://doi.org/10.1186/s12906-023-04142-1

Similar Items